Search results
Showing 1636 to 1650 of 9098 results
Evidence-based recommendations on cemiplimab (Libtayo) for recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults.
Evidence-based recommendations on mepolizumab (Nucala) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis (TA1155)
Evidence-based recommendations on rozanolixizumab (Rystiggo) for treating antibody-positive generalised myasthenia gravis in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma in adults.
Show all sections
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when a stem cell transplant is unsuitable.
NICE is unable to make a recommendation on imlunestrant (Inluriyo) for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1168
NICE is unable to make a recommendation on nogapendekin alfa inbakicept (Anktiva) with Bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours, that is unresponsive to BCG in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1163
Inebilizumab for treating immunoglobulin G4-related disease (terminated evaluation) (TA1151)
NICE is unable to make a recommendation on inebilizumab (Uplizna) for immunoglobulin G4-related disease. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1151
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.
Evidence-based recommendations on abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
NICE is unable to recommend the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. This is because The Medicines Company did not provide an evidence submission.
Show all sections
Sections for TA351
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA353
Evidence-based recommendation on mirvetuximab soravtansine (Elahere) for treating folate receptor-alpha (FR-alpha)-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.